I am sure that Silimed is not the only manufacturer of breast implants. Let's say that Silimed closes for an extended period. Sientra would then likely not be bound by its supplier contract with Silimed. Isn't there another company willing to take up the slack?
P.S.: company is trading almost at cash value. Marketing and development arms, and distribution network are almost worth 0 by the market today. Incredible.
OT: I do believe that last sentence has a dangling participle.
Is it that easy?
It just would be really hard to justify for any reasonable investor buying after a 200% run-up in the price on no new data. And that is the reason I am not buying here. I do not think it is cheap.
Today? Where? I see no SEC filings. Are you talking about the upcoming presentation? From the wording, I see no evidence that there will be any new data analysis forthcoming. The real event will be sudden and unexpected by most -- further trial analysis and FDA discussion info.
Did you delete my post, jaybull? Read the SEC form. It is not a 13D and it does not mention any wording as you describe.
Yes, it's high. The stock price was at one point 15 cents this year, and 60 cents AFTER the preliminary partial data release a few months ago. No data since then.
They might have added 1 or 2, but yes, it is accurate... the main compound was purchased years ago and all they are doing is outsourcing trial production and running some simple tests with it and donepezil.
A wash sale means the price falls beyond your purchase price, and you sell and rebuy to put the sale as a loss for the calendar year. That means you expect the price to fall, except that is not what you were indicating in the rest of your sentence...
And no. A 13D is not a Form D. Have you ever used the SEC website or do you just go by rumors? "Notice of Exempt Offering of Securities, item 06b". Read it.